OakChart

Procept BioRobotics Corp

PRCTHealthcare·Medical Devices·USA·Small·NASD·Nov 11 • 9:40 AM ET

23.09+0.05 (0.20%)
2026-11-11 15:41 CET
Market cap
1,326.21 USD m
Revenue, TTM
352.30 USD m
Net income, TTM
-114.86 USD m
Free cash flow, TTM
-85.07 USD m
EPS diluted, TTM
-2.03
P/E
-
Compare

Price

PRCT against its 20, 50 and 200-day averages
2050200missearnings
20.0025.0030.002.7M5.5MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PRCTclose 23.1020-day 20.0550-day 19.43200-day 22.9623.10

39.4% under 38.11 on 5 Dec 2025. Last 15 sessions, 32.0% high to low

Profile

PRCT
52-week range, 30% of the way up
16.6738.11

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating BPH. The firm's proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The company was founded by Nikolai Aljuri and Rodney C. Perkins in 2007 and is headquartered in San Jose, CA.

IndexRUT
Employees888
IPOSep 15, 2021
Beta0.81
ATR, 14d1.37
Rel volume0.21
Short float14.32%
Insider own4.63%
Inst own97.15%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.33B
Enterprise Value1.19B
Income-114.86M
Sales352.30M
Book/sh5.73
Cash/sh3.80
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees888
IPOSep 15, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S3.77
P/B4.03
P/C6.09
P/FCF-
EV/EBITDA-
EV/Sales3.37
Quick Ratio4.72
Current Ratio5.88
Debt/Eq0.23
LT Debt/Eq0.23
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.03
EPS next Y-1.22
EPS next Q-0.23
EPS this Y0.16%
EPS next Y28.68%
EPS next 5Y20.54%
EPS past 3/5Y4.30% -7.02%
Sales past 3/5Y60.14% 109.04%
EPS Y/Y TTM-31.69%
Sales Y/Y TTM17.47%
EPS Q/Q-20.41%
Sales Q/Q17.96%
EarningsNov 04 AMC
EPS/Sales Surpr.-17.50% -2.22%

Ownership

Insider Own4.63%
Insider Trans0.65%
Inst Own97.15%
Inst Trans-7.03%
ROA-23.31%
ROE-32.39%
ROIC-28.48%
Gross Margin64.66%
Oper. Margin-33.61%
Profit Margin-32.60%
SMA2015.16%
SMA5018.85%
SMA2000.57%
Trades-

Technical

Shs Outstand57.44M
Shs Float54.87M
Short Float14.32%
Short Ratio6.24
Short Interest7.86M
52W High38.11 -39.40%
52W Low16.67 38.58%
Volatility11.31% 6.92%
ATR (14)1.37
RSI (14)66.53
Beta0.81
Rel Volume0.21
Avg Volume1.26M
Volume19,266

Performance

Perf Week6.63%
Perf Month20.92%
Perf Quarter5.22%
Perf Half Y-10.14%
Perf YTD-26.59%
Perf Year-26.31%
Perf 3Y-25.50%
Perf 5Y-44.89%
Perf 10Y-
Recom2.47
Target Price22.75
Prev Close23.05
Price23.09
Change %0.20%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 07, 2026InitiatedBBarclaysOverweight$30+29.9%
Aug 05, 2026DowngradeWWilliam BlairOutperform → Mkt Perform
Aug 05, 2026DowngradeWWells FargoOverweight → Equal Weight$19-17.7%
Jul 28, 2026DowngradeUUBSBuy → Neutral$20-13.4%
Jul 06, 2026DowngradeTTruistBuy → Hold$25+8.2%
Jun 24, 2026InitiatedEEvercore ISIOutperform$30+29.9%
Jun 11, 2026DowngradeLLeerink PartnersOutperform → Market Perform$29+25.6%
Mar 06, 2026InitiatedRRobert W. BairdNeutral$30+29.9%
Feb 26, 2026DowngradeOOppenheimerOutperform → Perform
Feb 26, 2026DowngradeBBofA SecuritiesNeutral → Underperform$20-13.4%

Peers

Mkt cap
TickerCompanyMkt cap
BSXBoston Scientific Corp64.20B
TFXTeleflex Incorporated6.15B
PROFProfound Medical Corp278.39M
ISRGIntuitive Surgical Inc156.05B
SSIISS Innovations International Inc320.77M
CNMDConmed Corp1.52B
SYKStryker Corp121.61B
SIBNSI-BONE Inc1.14B
MDTMedtronic Plc128.97B
BDXBecton Dickinson & Co57.82B

Insider trading

latest 14 of 30
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Sharma PoojaChief Strat/Marketing OfficerNov 06 '26Sale19.714,71092,853106,471Nov 06 06:14 PM
Sharma PoojaOfficerNov 06 '26Proposed Sale19.714,71092,853Nov 06 03:21 PM
Nouri AlalehEVP, CLO, CORP. SEC.Sep 09 '26Sale20.952976,223127,737Sep 10 04:45 PM
Templin Barry LEVP, Chief Technology OfficerSep 09 '26Sale20.953737,81594,826Sep 10 04:44 PM
Waters KevinEVP, CFOSep 09 '26Sale20.953737,815180,355Sep 10 04:42 PM
Nouri AlalehOfficerSep 09 '26Proposed Sale20.952976,223Sep 09 03:15 PM
Templin Barry LOfficerSep 09 '26Proposed Sale20.953737,816Sep 09 03:14 PM
Waters KevinOfficerSep 09 '26Proposed Sale20.953737,816Sep 09 03:12 PM
Wood Larry LPresident, CEOAug 07 '26Buy20.8523,900498,31523,900Aug 10 06:07 AM
Nouri AlalehEVP, CLO, CORP. SEC.Jun 08 '26Sale28.482858,117105,069Jun 10 04:21 PM
Waters KevinEVP, CFOJun 08 '26Sale28.4835710,167151,201Jun 10 04:18 PM
Templin Barry LEVP, Chief Technology OfficerJun 08 '26Sale28.4835810,19568,953Jun 10 04:15 PM
Nouri AlalehOfficerJun 08 '26Proposed Sale28.482858,117Jun 08 04:34 PM
Waters KevinOfficerJun 08 '26Proposed Sale28.4835710,167Jun 08 04:09 PM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VXFVanguard Extended Market Index ETFAUM: 30.47B
BOTZGlobal X Funds Global X Robotics & Artificial Intelligence ETFAUM: 2.96B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IHIiShares U.S. Medical Devices ETFAUM: 4.07B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B

News

latest 14 of 206
  • PROCEPT BioRobotics Misses As U.S. Procedures Stall Sequentially, Leaving A Steep Fourth Quarter To Carry Its Reaffirmed Guidance (Earnings Whispers) +7.39% -6.42%
  • PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance (GlobeNewswire)
  • PROCEPT's Third Quarter Tests Whether Legacy AquaBeam Weakness Has Bottomed After Two Procedure Cuts (Earnings Whispers)
  • PROCEPT BioRobotics to Report Third Quarter 2026 Financial Results on November 4th, 2026 (GlobeNewswire) +6.36%
  • Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls (The Fly)
  • Loading…
  • Kaplan Fox Encourages PROCEPT BioRobotics Corporation (PRCT) Investors With Substantial Losses to Contact the Firm Before September 22, 2026 (Newsfile)
  • Kaplan Fox Reminds PROCEPT BioRobotics Corporation (PRCT) Investors That They Have Until September 22, 2026 to Move for Lead Plaintiff (Newsfile)
  • LAWSUIT NOTICE: NASDAQ: PRCT Investors who lost money with PROCEPT BioRobotics Corporation shares should contact the Shareholders Foundation (PR Newswire) -8.18%
  • Kaplan Fox Encourages PROCEPT BioRobotics Corporation (PRCT) Investors Who Suffered Losses to Seek a Leadership Role Before September 22, 2026 (Newsfile)
  • PROCEPT BioRobotics to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026 (GlobeNewswire)
  • PROCEPT BioRobotics Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PRCT (PR Newswire)
  • PRCT Shareholders Have Rights - If You Lost Money Investing in PROCEPT BioRobotics Corporation Contact Robbins LLP for Information About Recovering Your Losses (PR Newswire) +5.44%
  • PRCT Investor Announcement: PROCEPT BioRobotics Sued on behalf of Investors to Recover Losses after Artificially Inflated Revenue Leads to 18% Stock Drop (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.460-0.392-0.46098.29100.5215
2026Q22026-08-04-0.470-0.462-0.47194.5092.7713
2026Q12026-04-29-0.560-0.563-0.56083.1380.5213
2025Q42026-02-25-0.530-0.324-0.53276.3893.7714
2025Q32025-11-04-0.380-0.413-0.38483.3380.8413
2025Q22025-08-06-0.350-0.415-0.35379.1876.9812
2025Q12025-04-24-0.450-0.490-0.45069.1665.4410
2024Q42025-02-25-0.350-0.339-0.35068.2466.8210
2024Q32024-10-28-0.400-0.489-0.40358.3753.307
2024Q22024-08-01-0.500-0.523-0.49653.3550.108
2024Q12024-05-01-0.510-0.555-0.50944.5441.588
2023Q42024-02-27-0.540-0.438-0.54443.5841.798
2023Q32023-11-01-0.510-0.526-0.51035.1034.099
2023Q22023-07-27-0.560-0.571-0.56033.1030.318
2023Q12023-04-27-0.630-0.582-0.63224.4024.367
2022Q42023-02-28-0.630-0.544-0.62923.7822.917

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-3.630-3.040-1.37034.4733.37
2022FY-1.960-1.880-1.96375.0174.15
2023FY-2.240-2.138-2.241136.19134.44
2024FY-1.750-1.742-1.754224.5223.93
2025FY-1.720-1.525-1.720308.05326.38
2026FY--1.717--395.24
2027FY--1.225--474.02
2028FY--0.863--553.26
2029FY--0.503--613.98
2030FY-0.640--705.9

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-051382119.64114.7125.6
2026Q4S2026-11-041310117.8113.46122.4
2026Q4S2026-10-191310117.8113.46122.4
2026Q4S2026-10-161325117.8113.46122.4
2026Q4S2026-10-131316117.59113.46122.4
2026Q4S2026-09-081316117.59113.46122.4
2026Q4S2026-09-051316117.59113.46122.4
2026Q4S2026-09-021326117.59113.46122.4
2026Q4S2026-08-281326117.59113.46122.4
2026Q4S2026-08-241326117.59113.46122.41
2026Q4S2026-08-191327117.59113.46122.41
2026Q4S2026-08-121327117.59113.46122.4
2026Q4S2026-08-051327117.62113.46122.4
2026Q4S2026-07-301322119.18115.52126.41

Estimate history

EPS, annual-0.97-1.226-1.37-1.963-2.241-1.754-1.721-2.0254
Period2019202020212022202320242025TTM
EPS, quarterly-0.403-0.35-0.45-0.353-0.384-0.532-0.56-0.471-0.463
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual6.1697.71734.47375.014136.191224.498308.054352.3
Period2019202020212022202320242025TTM
Sales, quarterly58.3768.23669.16279.18283.32776.38383.13294.49898.291
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual43.25343.25343.67644.82850.77154.71856.32357.439
Period2019202020212022202320242025MRQ
Shares, quarterly52.14654.71855.27855.57755.8756.32356.89757.24757.439
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue352.30308.05224.50136.1975.0134.477.726.17
Cost of Goods Sold Incl. D&A124.52111.8387.4065.1437.9318.618.978.05
Gross Profit227.79196.23137.1071.0537.0915.87-1.25-1.89
Selling, General and Administrative Excl. Other346.20300.08233.71180.22117.8170.0346.5541.66
Research and Development80.6371.2862.3048.4528.9818.9916.2713.15
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-118.41-103.86-96.61-109.17-80.72-54.16-47.80-43.55
Interest Expense3.413.594.184.005.185.815.260.72
Unusual Expense0.000.000.110.113.54-0.200.12-1.20
Net Income Before Taxes-114.68-95.38-91.41-105.90-87.15-59.85-53.02-41.98
Income Taxes0.180.190.000.000.000.000.000.00
Consolidated Net Income-114.86-95.57-91.41-105.90-87.15-59.85-53.02-41.98
Net Income From Continuing Operations-114.86-95.57-91.41-105.90-87.15-59.85-53.02-41.98
Net Income-114.86-95.57-91.41-105.90-87.15-59.85-53.02-41.98
EPS (Recurring)-2.00-1.72-1.75-2.24-1.91-1.37-1.22-0.99
EPS (Basic, Before Extraordinaries)-2.03-1.72-1.75-2.24-1.96-1.37-1.23-0.97
EPS (Diluted)-2.03-1.72-1.75-2.24-1.96-1.37-1.23-0.97
EBITDA-110.44-97.47-91.38-105.36-76.41-51.19-45.10-42.06
Non-Operating Income (Expense)7.1512.069.507.382.29-0.080.161.10
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense42.2937.6131.8419.1310.673.802.171.99
Price To Sales Ratio2.965.6718.7014.5424.5931.69--
Gross Margin64.6663.7061.0752.1749.4446.02-16.26-30.56
Operating Margin-33.61-33.71-43.04-80.16-107.61-157.12-619.44-705.95
Net Margin-32.60-31.02-40.72-77.76-116.18-173.62-687.04-680.42
Shares Outstanding57.4456.3254.7250.7744.8343.6843.2543.25
Market Capitalization1,326.211,326.214,379.862,115.321,857.421,087.231,092.02-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue98.2994.5083.1376.3883.3379.1869.1668.24
Cost of Goods Sold Incl. D&A33.1432.1229.1830.0730.9429.0225.0024.56
Gross Profit65.1562.3853.9546.3152.3950.1644.1643.67
Selling, General and Administrative Excl. Other92.5289.7786.5577.3575.5872.3571.6063.38
Research and Development20.0120.1021.4619.0616.5716.0416.4015.07
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-27.38-27.39-32.61-31.04-23.19-22.19-27.44-19.71
Interest Expense0.860.840.820.890.920.900.880.97
Unusual Expense0.000.000.000.000.000.000.00-
Net Income Before Taxes-26.57-26.77-31.68-29.66-21.41-19.58-24.74-18.86
Income Taxes-0.060.09-0.040.190.000.000.000.00
Consolidated Net Income-26.52-26.86-31.64-29.84-21.41-19.58-24.74-18.86
Net Income From Continuing Operations-26.52-26.86-31.64-29.84-21.41-19.58-24.74-18.86
Net Income-26.52-26.86-31.64-29.84-21.41-19.58-24.74-18.86
EPS (Recurring)-0.46-0.47-0.56-0.53-0.38-0.35-0.45-0.35
EPS (Basic, Before Extraordinaries)-0.46-0.47-0.56-0.53-0.38-0.35-0.45-0.35
EPS (Diluted)-0.46-0.47-0.56-0.53-0.38-0.35-0.45-0.35
EBITDA-24.84-25.40-30.87-29.33-21.57-20.60-25.96-18.26
Non-Operating Income (Expense)1.661.471.742.282.703.513.581.82
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense11.9111.4810.338.5714.4912.1610.119.09
Price To Sales Ratio2.963.824.395.736.6311.6212.8419.31
Gross Margin66.2866.0164.8960.6362.8763.3563.8564.00
Operating Margin-27.85-28.98-39.22-40.64-27.83-28.02-39.67-28.89
Net Margin-26.98-28.42-38.06-39.07-25.70-24.73-35.77-27.63
Shares Outstanding57.4457.2556.9056.3255.8755.5855.2854.72
Market Capitalization1,326.211,285.231,410.321,757.941,985.653,186.933,193.744,379.86

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments286.50333.73257.22222.64304.32100.1342.02
Short Term Receivables83.5383.5048.3815.274.461.551.10
Inventories70.6956.1739.7628.5413.987.486.69
Other Current Assets9.658.455.216.173.410.740.55
Total Current Assets450.38481.84350.57272.63326.17109.9050.36
Net Property, Plant & Equipment47.9445.6548.9932.148.3212.918.27
Total Investments and Advances3.043.043.043.040.780.780.69
Intangible Assets0.710.931.201.481.752.022.29
Other Assets6.022.560.920.050.000.360.38
Total Assets508.08534.02404.72309.33337.02125.9761.99
Short Term Debt Incl. Current Port. of LT Debt2.211.911.682.132.106.260.00
Accounts Payable17.2910.0313.509.392.031.241.44
Other Current Liabilities46.3041.1930.7523.7712.117.035.35
Total Current Liabilities65.8053.1345.9335.2916.2414.536.79
Long Term Debt76.2778.3477.5275.1951.9948.5023.22
Provision for Risks Charges0.150.320.520.000.200.200.20
Other Liabilities0.000.000.001.781.501.782.55
Total Liabilities142.21131.80123.97112.2669.9365.0132.76
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00243.85173.07
Common Equity365.87402.22280.75197.07267.09-182.89-143.84
Total Shareholders Equity365.87402.22280.75197.07267.0960.9629.23
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity365.87402.22280.75197.07267.0960.9629.23
Total Liabilities & Stockholders Equity508.08534.02404.72309.33337.02125.9761.99
Book Value Per Share6.507.355.534.406.12-4.23-3.33
Tangible Book Value Per Share6.487.335.514.366.08-4.28-3.38
Full-Time Employees888756626428234--
Price to Book Ratio4.0317.417.078.414.093.85-
Return on Assets-18.34-19.48-29.66-26.97-25.85-56.41-
Return on Equity-24.89-26.77-44.32-37.55-36.49-117.57-
Return on Invested Capital-21.62-19.02-29.56-32.01-18.76-48.44-80.02
Quick Ratio5.778.016.776.9219.227.056.43
Current Ratio6.859.077.637.7320.087.577.42

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-114.86-95.57-91.41-105.90-87.15-59.85-53.02-41.98
Depreciation7.976.395.233.814.322.982.701.49
Other Funds (Non Cash)53.5948.0434.2920.2513.944.252.460.20
Funds from Operations-53.30-41.15-51.89-81.84-68.89-52.63-47.86-40.29
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-23.39-7.84-47.33-26.16-11.49-4.71-0.48-3.53
Cash from Operating Activities-76.69-48.98-99.21-108.00-80.38-57.33-48.34-43.82
Capital Expenditures-8.38-9.36-4.41-25.21-2.65-0.59-0.23-7.61
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.0050.76
Purchase of Investments0.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.0050.76
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-8.38-9.36-4.41-25.21-2.65-0.59-0.2343.15
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock9.2611.19180.12167.796.42262.1282.091.99
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock9.2611.19180.12167.796.42262.1282.091.99
Proceedsfrom Stock Options7.176.36169.05165.312.41257.9379.801.69
Issuance or Reduction of Debt, Net0.000.000.000.00-2.810.0024.6824.53
Change in Long Term Debt0.000.000.000.00-2.810.0024.6824.53
Issuance of Long Term Debt0.000.000.000.0051.200.0024.6824.53
Reduction of Long Term Debt0.000.000.000.00-54.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities9.2611.19180.12167.793.61262.12106.7726.53
Exchange Rate Effect-0.10-0.07------
Net Change in Cash-75.91-47.2276.5034.59-79.42204.1958.2025.86
Free Cash Flow-85.07-58.34-103.62-133.21-83.03-57.93-48.58-51.43
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments218.37227.91245.64286.50294.28302.72
Short Term Receivables105.03107.6196.3983.5384.5080.82
Inventories81.4177.0677.5470.6966.7267.03
Other Current Assets8.847.218.479.658.717.09
Total Current Assets413.65419.79428.03450.38454.21457.66
Net Property, Plant & Equipment46.5448.6048.9047.9447.9346.86
Total Investments and Advances3.043.043.043.043.043.04
Intangible Assets0.500.570.640.710.730.80
Other Assets5.343.442.686.022.411.95
Total Assets473.76479.35487.06508.08511.54513.05
Short Term Debt Incl. Current Port. of LT Debt2.652.502.362.212.132.06
Accounts Payable16.7215.0718.8517.2911.1211.78
Other Current Liabilities50.9846.6242.4346.3040.6535.88
Total Current Liabilities70.3564.2063.6465.8053.9049.73
Long Term Debt74.3475.0075.6476.2776.7977.31
Provision for Risks Charges0.000.000.000.150.000.00
Other Liabilities0.160.090.120.000.580.22
Total Liabilities144.85139.28139.40142.21131.26127.26
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity328.91340.07347.67365.87380.28385.80
Total Shareholders Equity328.91340.07347.67365.87380.28385.80
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity328.91340.07347.67365.87380.28385.80
Total Liabilities & Stockholders Equity473.76479.35487.06508.08511.54513.05
Book Value Per Share5.735.946.116.506.816.94
Tangible Book Value Per Share5.725.936.106.486.796.93
Full-Time Employees---888--
Price to Book Ratio4.033.703.854.625.148.18
Return on Assets-23.31-22.12-20.36-18.34-19.10-18.96
Return on Equity-32.39-30.24-27.81-24.89-27.22-26.40
Return on Invested Capital-6.58-6.47-7.47-6.75-4.68-4.23
Quick Ratio4.725.345.515.777.197.86
Current Ratio5.886.546.736.858.439.20

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-26.52-26.86-31.64-29.84-21.41-19.58
Depreciation2.541.991.741.711.621.59
Other Funds (Non Cash)14.7715.3513.689.7915.1912.45
Funds from Operations-9.20-9.52-16.22-18.35-4.60-5.54
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.22-9.73-21.908.02-2.03-9.50
Cash from Operating Activities-8.98-19.25-38.13-10.33-6.63-15.04
Capital Expenditures-0.67-2.95-2.91-1.85-2.87-2.80
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.67-2.95-2.91-1.85-2.87-2.80
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.104.500.224.441.084.38
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.104.500.224.441.084.38
Proceedsfrom Stock Options0.004.310.002.86-0.003.50
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.104.500.224.441.084.38
Exchange Rate Effect0.01-0.02-0.04-0.04-0.01-
Net Change in Cash-9.54-17.73-40.86-7.78-8.44-13.49
Free Cash Flow-9.65-22.20-41.04-12.18-9.50-17.84

Revenue breakdown

Hand Pieces and Other Consumables2024: 121.46M 2025: 181.45M
Service2024: 12.74M 2025: 20.48M
System Sales and Rentals2024: 90.30M 2025: 106.13M
Non-US2024: 24.03M 2025: 37.68M
United States2024: 200.47M 2025: 270.38M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3014.32%7.9M54.9M1.34M
2026-10-1513.73%7.5M54.6M1.43M
2026-09-3013.60%7.4M54.6M1.47M
2026-09-1513.62%7.4M54.6M1.57M
2026-08-3113.27%7.2M54.6M1.57M
2026-08-1414.11%7.7M54.6M1.67M
2026-07-3112.91%7.1M55.0M1.57M
2026-07-1514.20%7.8M54.6M1.58M
2026-06-3014.02%7.7M54.6M1.53M
2026-06-1513.94%7.6M54.6M1.41M
2026-05-2912.39%6.8M54.7M1.58M
2026-05-1512.35%6.7M54.4M1.78M
2026-04-3011.04%6.0M54.4M1.70M
2026-04-1510.78%5.8M54.1M1.66M
2026-03-3110.81%5.9M54.3M1.62M
2026-03-1311.98%6.5M54.3M1.58M
2026-02-2711.76%6.4M54.3M1.45M
2026-02-1313.00%7.0M53.8M1.29M
2026-01-3013.36%7.2M53.8M1.41M
2026-01-1512.23%6.6M53.8M1.42M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.0015.67-2.000.00---
call5.000.000.000.00-0.000.00---
call7.500.000.000.00-0.000.00---
call10.000.000.000.00-0.000.00---
call12.500.000.007.24-5.000.00---
call15.000.000.004.81-5.000.00---
call17.500.000.004.50-14.000.00---
call20.000.000.001.12-2450.00---
call22.500.000.000.75-1590.00---
call25.000.000.000.40-2,3950.00---
call27.500.000.000.08-2830.00---
call30.000.000.000.01-1270.00---
put2.500.000.000.00-0.000.00---
put5.000.000.000.00-0.000.00---
put7.500.000.000.00-0.000.00---
put10.000.000.000.00-0.000.00---
put12.500.000.000.38-6.000.00---
put15.000.000.000.05-2170.00---
put17.500.000.000.40-2,1260.00---
put20.000.000.000.80-8.000.00---
put22.500.000.002.30-20.000.00---
put25.000.000.003.30-2.000.00---
put27.500.000.006.27-1.000.00---
put30.000.000.000.00-0.000.00---

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-06144Filing for proposed sale of securities under Rule 144.SEC
2026-11-064Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-30SCHEDULE 13G/ASEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-02SEC
2026-10-053Initial statement of beneficial ownership of securities2026-10-02SEC
2026-10-028-KCurrent report2026-10-02SEC
2026-09-248-KCurrent report2026-09-23SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-09144Filing for proposed sale of securities under Rule 144.SEC
2026-09-09144Filing for proposed sale of securities under Rule 144.SEC
2026-09-09144Filing for proposed sale of securities under Rule 144.SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-048-KCurrent report2026-08-04SEC
2026-07-29SCHEDULE 13G/ASEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110092.85K1
2026-100000
2026-090021.85K3
2026-08498.32K100
2026-070000
2026-060028.48K3
2026-050000
2026-040000
2026-0310.48M3573.52K6
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.8.56%
T. Rowe Price Investment Management, Inc.5.74%
BNP Paribas Asset Management Holding S.A.4.96%
VANGUARD PORTFOLIO MANAGEMENT LLC4.44%
VANGUARD CAPITAL MANAGEMENT LLC4.32%
STATE STREET CORP2.84%
PRICE T ROWE ASSOCIATES INC /MD/2.34%
GEODE CAPITAL MANAGEMENT, LLC2.33%
WELLINGTON MANAGEMENT GROUP LLP2.24%
FEDERATED HERMES, INC.2.20%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.00%
iShares Russell 2000 ETF2.56%
T. Rowe Price Small-Cap Stock Fund, Inc.2.32%
VANGUARD SMALL-CAP INDEX FUND2.18%
Janus Henderson Venture Fund1.56%
VANGUARD SMALL-CAP GROWTH INDEX FUND1.25%
T. Rowe Price Institutional Small-Cap Stock Fund1.22%
VANGUARD EXTENDED MARKET INDEX FUND1.15%
Federated Hermes MDT Small Cap Core Fund1.14%
T. Rowe Price New Horizons Fund, Inc.1.08%

OakChart. PRCT. Cached 15 minutes.